Strategic acquisitions PulseVet has changed ownership multiple times, including acquisition by The Wall Street Analyzer in 2022 and Zomedica Pharmaceuticals in 2021, signaling potential interest from buyers or partners in scaling or exit opportunities for sales discussions or channel partnerships.

Customer reach Industry partnerships with show associations and collegiate athletic leagues indicate active engagement with end users in equine and companion animal markets, suggesting opportunities to expand bundled offerings or sponsorships with event organizers and training programs.

Product expansion Recent device launches for companion animals and a focus on veterinary shockwave therapies across dogs and horses point to cross-sell opportunities for related devices, consumables, and service plans for clinics expanding shockwave or PRP therapies.

Market positioning As a market leader in shockwave therapy with a global footprint under prior ownership, there is potential to leverage legacy credibility to target clinics seeking proven technology, while exploring partnerships with distributors in regions where adoption is growing.

Financial cue With revenue under one million and a relatively lean team, there is appetite for scalable sales programs, channel partnerships, and value-based bundles designed to drive adoption in small to mid-size veterinary practices and performance-based marketing approaches.